Information on this company is supplied by EMIS which is part of Euromoney Institutional Investor plc, one of Europe's largest publishers and a constituent of the FTSE 250 index.
Full name: Zaklady Farmaceutyczne Polpharma S.A.
Previous name(s): Starogardzkie Zaklady Przemyslu Faramceutyczne POLFA P.P. ()
Starogardzkie Zaklady Farmauceutyczne Polfa (1995)
Legal Form: Public Limited Company
Operational Status: Operational
PL DUNS: 422195139
Incorporation Date: 2002
Polpharma is among the 20 largest generics companies in the world, with a turnover of approx. 1 billion dollars a year. It employs more than 7,500 people in Poland and in some foreign markets. The company has 7 production plants in Poland, Russia and Kazakhstan, and 7 centers of research and development. Polpharma Group's portfolio includes about 600 products, and another 200 are under development. Polpharma SA specializes in cardiology, gastroenterology and neurology. A significant part of the productMore
EMIS Benchmark Score
Import connections ('000)
Export connections ('000)
|Net sales revenue|
|Total operating revenue|
|Operating profit (EBIT)|
|Net Profit (Loss) for the Period|
|Operating Profit (EBIT) Margin|
|Return on Sales (ROS)|
|Return on Equity (ROE)|
|Debt to Equity|
|Company Tear Sheet|
|NAICS Industry Classification||✓||✕|
|Share Price information||✓||✕|
|Subsidiaries and Affiliates||✓||✕|
|Key Financial Highlights||✓||✕|
|Financial Performance Charts||✓||✕|
|Latest M&A and ECM Deals||✓||✕|
|EMIS Credit Analytics|
|EMIS Benchmark Score||✓||✕|
- or -
EMIS company profiles are part of a larger information service that combines company, industry and country data and analysis for over 120 emerging markets on a unique information platform.
If you need broad and deep coverage of one or many countries, you may be interested in subscribing. Request a demonstration of our full service and one of our account managers will be in touch.